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POTENTIAL MECHANISM OF ALENDRONATE INHIBITION UPON
OSTEOPHYTE FORMATION IN THE RAT MODEL OF POST-TRAUMATIC
OSTEOARTHRITIS: AN IN-VIVO MICRO-CT, ELECTRON PROBE AND
HISTOLOGIC STUDY
A. Panahifar1, W. Maksymowych2, M.R. Doschak1. 1Faculty of Pharmacy &
Pharmaceutical Sci., Univ. of Alberta, Edmonton, AB, Canada; 2Dept. of
Rheumatology, Faculty of Med., Univ. of Alberta, Edmonton, AB, Canada
Purpose: Our study focused on the reported ability of the
bisphosphonate drug Alendronate (ALN) to block osteophytosis in rat
models of post-traumatic osteoarthritis (PTOA), a process that the closely
related Risedronate has not been shown to inﬂuence. Our purpose was
to better elucidate the mechanism whereby ALN is seen to inhibit
osteophyte (OST) formation and slow disease progression in rat surgical
models of PTOA.
Methods: PTOA pathogenesis was induced in 12 rats by medial
meniscectomy (MMx) surgery. We utilized in-vivo microfocal computed
tomography (Micro-CT) to measure temporal bony adaptations at 4 and
8 weeks after surgery in those rats with or without ALN treatment, and
compared them to six sham-operated control rats. A pulse of elemental
Strontium (Sr) was administered by oral gavage in the last 10 days
to map bone turnover in developing PTOA using Electron Probe Micro
Analysis (EPMA). Histologic studies were then undertaken on safranin-
O/fast green and tetrachrome stained decalciﬁed sections to examine
articular cartilage health and OST formation.
Results: Micro-CT volumetric measurements of OST (Figure 1a) revealed
that ALN treatment inhibited OST development by 40% and 51% at 4 and
8 weeks after surgery, respectively. OST in ALN group were measured
with reduced BMD values (i.e., more cartilaginous in composition)
compared to the untreated MMx group. Histological examination
conﬁrmed the OST inhibitory effect of ALN, and provided evidence of
reduced articular cartilage degradation, compared to untreated MMx rats.
EPMA mapped uniform deposition of Sr tracer over actively remodeling
trabecular surfaces in normal control rats. That pattern, however, was
altered after MMx resulting in greater Sr signal localized to developing
OST margins (Figure 1b). ALN treatment reduced the incorporation of Sr
tracer in OST margins, conﬁrming the reduced mineralization of tissues
in developing OST.
Fig. 1. Bony osteophyte, detected using: (a) Micro-CT, (b) Sr EPMA,
(c) Histology.
Conclusions: Our study conﬁrmed that ALN administration will reduce
OST formation in a rat model of PTOA, partially through the inhibition
of secondary remodeling of OST. ALN preserved articular cartilage health
by inhibiting secondary bone turnover and/or sclerosis of periarticular
and subchondral bone. Our results support the indication of ALN in the
prevention of OST formation, which if administered immediately after
traumatic injury (over a transient therapeutic window), may prove an
effective disease-modifying drug treatment to slow the progression of
secondary OA.
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SUSTAINED STIMULATION OF CARTILAGE BIOSYNTHETIC ACTIVITY
AFTER INTRA-ARTICULAR INJECTION OF AN ENGINEERED IGF-1
F. Loffredo1, T. Vanelli2, J. Dong2, R.T. Lee1, P. Patwari1. 1Brigham and
Women’s Hosp., Cambridge, MA, USA; 2Biomeasure/IPSEN, Milford, MA, USA
Purpose: IGF-1 stimulates cartilage repair, but is not a practical arthritis
therapy due to its short half-life and systemic side-effects. Fusing
IGF-1 with a heparin-binding domain generates an IGF-1 (termed
“HB-IGF-1”) that sticks to cartilage through binding to its abundant
chondroitin sulfated proteoglycans. In the present study we tested
whether intra-articular injection of HB-IGF-1 provides long-term delivery
and stimulation of cartilage biosynthetic activity in vivo.
Methods: Proteins: HB-IGF-1 was created by N-terminal fusion of a
modiﬁed heparin-binding domain from human HB-EGF with human
IGF-1. The protein was puriﬁed after expression in E. coli. Recombinant
human IGF-1 (Increlex) was from Ipsen. Rat studies: 3-month-old Lewis
rats received intra-articular injection of 100 microliters saline containing
100 micrograms HB-IGF-1, IGF-1, or no additions. Ex vivo proteoglycan
biosynthesis: The menisci of the injected joint were cleaned of all attached
connective tissues and then incubated in serum-free medium with 35S-
sulfate for 18 hours. After washing in cold medium and digesting the
cartilage, radiolabel incorporation was measured by liquid scintillation.
Results: After intra-articular injection, unmodiﬁed IGF-1 was not
detectable in extracts of harvested cartilage by Western analysis.
In contrast, HB-IGF-1 remained detectable in articular and meniscal
cartilages for 6–8 days after injection. Two days after injection,
unmodiﬁed IGF-1 had no effect on meniscal cartilage proteoglycan
synthesis, whereas HB-IGF-1 caused a 2.1-fold stimulation of
proteoglycan synthesis relative to saline only (N =5 rats/group, P < 0.05 by
t-test; Figure 1). Four days after injection, there remained a signiﬁcant
stimulation by HB-IGF-1 (1.8-fold, P < 0.05), but not IGF-1, relative to
saline.
Conclusions: These data demonstrate that a heparin-binding IGF-1
fusion protein provides sustained delivery and functional effect in
vivo after intra-articular injection in rats. Heparin-binding fusions may
represent a new strategy for sustained local delivery of therapeutic
proteins to cartilage.
Fig. 1.
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SELECTIVE INHIBITION OF INDUCIBLE NITRIC OXIDE SYNTHASE
PREVENTS LIPID PEROXIDATION IN CARTILAGE FROM PATIENTS
WITH OSTEOARTHRITIS
M. Bentz, C. Zaouter, M. Osman, Q. Shi, F. Moldovan, J. Fernandes,
M. Benderdour. Univ. of Montreal, Montreal, QC, Canada
Purpose: Emerging evidence indicates that nitric oxide (NO), which
is increased in osteoarthritic (OA) cartilage, plays a role in
4-hydroxynonenal (HNE) generation through peroxynitrite formation.
HNE is considered as the most reactive product of lipid peroxidation
(LPO). We have previously reported that HNE levels in synovial ﬂuids
are more elevated in knees of OA patients compared to healthy. We also
demonstrated that HNE induces a panoply of inﬂammatory and catabolic
mediators known for their implication in OA cartilage degradation. The
aim of the present study was to investigate the ability of inducible NO
synthase (iNOS) inhibitor, L-NIL, to prevent HNE generation through NO
inhibition in human OA chondrocytes.
Methods: Cells and cartilage explants were treated with or without
either an NO generator (SIN or interleukin 1beta (IL-1b)) or HNE
in absence or presence of L-NIL. Protein expression of both iNOS
and free-radical-generating NOX subunit p47 (phox) were done by
Western blot. iNOS mRNA detection was measured by real-time
RT-PCR. HNE production was analysed by ELISA, Western blot and
immunohistochemistry. S-nitrosylated proteins were evaluated by
